Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition

Journal of Molecular and Cellular Cardiology

Volumn 34, Issue 6, 2002, Pages 617-627

  Kaikita, Koichi ^a   Schoenhard, John A ^a   Painter, Corrie A ^a   Ripley, Robert T ^a   Brown, Nancy J ^b   Fogo, Agnes B ^a   Vaughan, Douglas E ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Collagen; Hypertension; Nitric oxide synthase; Plasminogen activators; Vascular fibrosis

Indexed keywords

MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; ENZYME INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FIBROSIS; HYPERTENSION; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; ZYMOGRAPHY; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CORONARY BLOOD VESSEL; DRUG ANTAGONISM; HEMODYNAMICS; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA;

ANIMALS; BODY WEIGHT; CORONARY DISEASE; CORONARY VESSELS; ENZYME INHIBITORS; FIBROSIS; HEMODYNAMIC PROCESSES; HYPERTENSION; MICE; MICE, INBRED C57BL; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036623991     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.2002.2001     Document Type: Article

References (46)

1. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993: 329: 2002-2012.
2. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-666.
3. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
4. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 1992; 90: 278-281.
5. Ribeiro MO, Antunes E, De Nucci G, Lovisolo SM, Zatz R. Chronic inhibition of nitric oxide synthesis: a new model of arterial hypertension. Hypertension 1992; 20: 298-303.
6. Zatz R, Baylis C. Chronic nitric oxide inhibition model six years on. Hypertension 1998; 32: 958-964.
7. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
8. Shesely EG, Maeda N, Kim HS, Desai KM, Krege JH, Laubach VE, Sherman PA, Sessa WC, Smithies O. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1996; 93: 13176-13181.
9. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997: 99: 278-287.
10. Tharaux PL, Chatziantoniou C, Casellas D, Fouassier L, Ardaillou R, Dussaule J-C. Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats. Circulation 1999: 99: 2185-2191.
11. Boffa JJ, Tharaux PL, Placier S, Ardaillou R, Dussaule JC, Chatziantoniou C. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 1999; 100: 1901-1908.
12. Katoh M, Egashira K, Mitsui T, Chishima S, Takeshita A, Narita H. Angiotensin-converting enzyme inhibition prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J Mol Cell Cardiol 2000; 32: 73-83.
13. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989; 9: 87-115.
14. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-3055.
15. 3 binding to vitronectin. Nature 1996; 383: 441-443.
16. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Medicine 1999; 5: 1135-1142.
17. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 1995; 96: 1621-1630.
18. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164-172.
19. Kaikita K, Fogo AB, Ma L-J, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104: 839-844.
20. Werb Z, Mainardi CL, Vater CA, Harris EDJ. Endogenous activation of latent collagenase by rheumatoid synovial cells: evidence for a role of plasminogen activator. N Engl J Med 1977; 296: 1017-1023.
21. He C, Wilhelm SM, Pentland AP, Marmer BL, Grant GA. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632-2636.
22. Salame MY, Samani NJ, Masood I, Debono DP. Expression of the plasminogen activator system in the human vascular wall. Atherosclerosis 2000; 152: 19-28.
23. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1432-1443.
24. Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-2755.
25. Carmeliet P, Stassen JM, Schoonjans L, Ream B, Van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-2760.
26. Carmeliet P, Schoonjans L, Kieckens L, Beam B, Degen J, Bronson R, Devos R, Van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424.
27. Prendergast GC, Diamond LE, Dahl D, Cole MD. The c-myc-regulated gene mr1 encodes plasminogen activator inhibitor 1. Mol Cell Biol 1990; 10: 1265-1269.
28. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995; 9: 974-980.
29. Galis ZS, Sukhova GK, Lark MW, Libbyccc P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
30. Dubin D, Pratt RE, Hui KY, Dzau VJ. Characterization of prorenin activation using a synthetic peptide substrate. J Hypertens 1991; 9: 483-486.
31. Derkx FH, Brommer EJ, Boomsma F, Schalekamp MA. Activation of plasma prorenin by plasminogen activators in vitro and increase in plasma renin after stimulation of fibrinolytic activity in vivo. Clin Exp Hypertens 1982; 4: 2247-2258.
32. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res 1998; 83: 743-751.
33. G-nitro L-arginine methyl ester due to converting enzyme inhibition. J Cardiovasc Pharmacol 1996; 28: 142-148.
34. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-1438.
35. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
36. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32: 965-971.
37. Feener EP, Northrup JM, Aiello LP, King, GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95: 1353-1362.
38. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93: 1073-1078.
39. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells: role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18: 1771-1779.
40. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 1998; 32: 273-279.
41. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-β1-like molecule by plasmin during co-culture. J Cell Biol 1989; 109: 309-315.
42. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem 1995; 270: 4689-4696.
43. Munger JS, Harpel JG, Gleizes P-E, Mazzieri R, Nunes I, Rifkin DB. Latent transforming growth factor-β: structural features and mechanisms of activation. Kidney Int 1997; 51: 1376-1382.
44. 2-macroglobulin. J Biol Chem 1987; 262: 14090-14099.
45. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
46. G-nitro-L-arginine methyl ester-induced hypertension. Modulation of proinflammatory signals. Hypertension 2000; 36: 103-109.